These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Clinical utility of Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622 [TBL] [Abstract][Full Text] [Related]
29. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115 [TBL] [Abstract][Full Text] [Related]
30. Parghane RV; Talole S; Basu S Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123 [TBL] [Abstract][Full Text] [Related]
31. First-in-Humans Study of the SSTR Antagonist Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401 [TBL] [Abstract][Full Text] [Related]
32. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590 [TBL] [Abstract][Full Text] [Related]
33. Paganelli G; Sansovini M; Nicolini S; Grassi I; Ibrahim T; Amadori E; Di Iorio V; Monti M; Scarpi E; Bongiovanni A; Altini M; Urso L; Cittanti C; Matteucci F; Severi S Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):152-160. PubMed ID: 32472437 [TBL] [Abstract][Full Text] [Related]
34. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432 [TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of peptide receptor radionuclide therapy with Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700 [TBL] [Abstract][Full Text] [Related]
36. Additional hepatic Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988 [TBL] [Abstract][Full Text] [Related]
37. Multimodal Imaging of 2-Cycle PRRT with Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703 [TBL] [Abstract][Full Text] [Related]
38. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT? Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704 [TBL] [Abstract][Full Text] [Related]
39. Prevalence of hitherto unknown brain meningioma detected on Parghane RV; Talole S; Basu S World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748 [TBL] [Abstract][Full Text] [Related]
40. Prediction of Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]